Trillium Therapeutics Acquires Fluorinov Pharma

Trillium Therapeutics Inc. (NASDAQ:TRIL,TSX:TR;) has acquired all of the outstanding shares of privately-held Fluorinov Pharma Inc.
According to the press release:

The transaction combines Fluorinov’s pipeline of oncology therapeutics and risk-reduced drug discovery engine, with Trillium’s pool of innovative immuno-oncology therapies. The resulting impressive arsenal of clinical and near-clinical stage products is positioned to benefit greatly from the capital and development resources available to Trillium. The acquisition also reflects the strength of innovation within the province, as well as the current momentum behind biotechnology and product development expertise in Ontario.

Dr. Malik Slassi, Fluorinov’s founder and President commented:

Fluorinov is deeply appreciative of FACIT’s support in helping to develop the Company’s programs and therapies to a stage where well-respected leaders at Trillium have taken notice. We are excited about this new chapter with our colleagues at Trillium and are confident that the shared vision and an aggressive growth strategy will unlock the full value in the combined and strengthened pipeline of innovative therapies.

Click here to view the full press release.